Dr. Jim Young; Prof. Heiner C. Bucher
Status: completed Duration: Apr 2014 - Oct 2017
Most patients with HIV start antiretroviral therapy on a single tablet once a day regimen. However it is not clear whether single tablet regimens actually lead to better clinical outcomes. The best way to estimate the effect of reducing the pill burden of antiretroviral therapy is to compare single tablet regimens with multiple tablet regimens where all regimens contain the same drugs. We will investigate whether Atripla®, the first single tablet regimen, is non-inferior for both virological failure and progression to AIDS or death relative to two or three pill formulations of the same regimen. Using off-patent drugs in multiple tablet regimens instead of adding these drugs to more expensive single tablet regimens could lead to important cost savings.